Navigation Links
Dutasteride not a cost-effective way to prevent prostate cancer in some men
Date:2/8/2011

DALLAS Feb. 8, 2011 The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease, according to findings by a UT Southwestern Medical Center researcher.

In a study available in the January issue of Cancer Prevention Research, investigators found that the medication, at an annual cost of $1,400, is impractical when compared to the marginal impact on survival and quality of life in at-risk groups. The drug is indicated for the treatment of enlarged prostates but also is widely prescribed for chemoprevention.

"Because prostate cancer is the most common cancer in men, the implications of this data are significant since there could be millions of men who would be eligible for anti-cancer drugs," said Dr. Yair Lotan, associate professor of urology at UT Southwestern. "Prior to instituting a chemoprevention strategy to a large population, the utility and cost need to be well understood. Whether a medication improves survival, how it affects quality of life, and what its financial implications will be are all critical issues. Because dutasteride typically is prescribed for the lifetime of the patient, and therefore taken daily for decades, the cost issue is particularly relevant."

Prior research has shown that dutasteride reduced the relative risk of prostate cancer over a four-year period by 22.8 percent, but questions have remained about its cost-effectiveness. The current study analyzed the lifetime health-related costs of the drug in patients at greater risk of developing prostate cancer and compared them to other factors, such as quality and length of life.

Dr. Lotan and his colleague, Dr. Robert Svatek of UT Health Science Center at San Antonio, used a Markov probability model to compare the lifetime cost of taking dutasteride with no therapy. They used data from a previous trial and studies that evaluated outcomes of patients with prostate cancer, including treatment-related complications to create the model. The primary outcome was measured in quality-adjusted life years (QALY), which takes into account both quality and quantity of life.

"The study found that dutasteride was not cost-effective for chemoprevention unless and until a strategy is developed for targeting very high-risk patients and the cost of the drug decreases," said Dr. Lotan. "For the average man, the drug provides minimal survival benefits, and the reduction on treatment-related complications does not compensate for the high costs of every man taking the drug for many years."


'/>"/>

Contact: Rachel Skei Donihoo
rachel.donihoo@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. European Urology: Editorial about REDUCE trial underlines value of dutasteride
2. Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment
3. Web-based questionnaire can be cost-effective tool for survey responses
4. Testing African couples for HIV is cost-effective prevention strategy
5. Wider statin use could be cost-effective preventive measure, Stanford study finds
6. Centralized health care more cost-effective, offers better access to preventive services
7. Trauma center care cost-effective
8. UNC physician authors editorial on cost-effectiveness study for colon cancer screening
9. Colorectal cancer screening in Canada is cost-effective
10. Antiviral therapy during compensated cirrhosis most cost-effective approach
11. Hospital Focus 5 Announces Contract with Connecticut Hospital to Improve Quality, Productivity and Cost-Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Sam & Associates Insurance Agency, ... and related services to residents of the region, is embarking on a charity ... and wild lands. , Endangered Species International is committed to ending the anthropogenic ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... California and Nevada and LABS, Inc., announced the future opening of a CLIA ... screening and serology testing used to determine the suitability of potential organ ...
(Date:3/22/2017)... FL (PRWEB) , ... March 22, 2017 , ... An ... mosquitoes could occasionally transmit HIV, reports Leslie Norins, MD, PhD. He says ... cases of domestically transmitted Zika virus and in new infections with HIV. ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, ... therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that ... treatment of non-small cell lung cancer and small cell lung cancer. , Throughout ...
(Date:3/22/2017)... Oklahoma City, OK (PRWEB) , ... March 22, ... ... firm offering insurance and financial planning services to regional families and business owners, ... provide meaningful support to young people in the area. , A growing number ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... FALLS, N.J. , March 22, 2017  CANTEL MEDICAL ... Jorgen B. Hansen , President and CEO, will be presenting ... Conference at the Westin Grand Central Hotel in ... Wednesday, April 5, 2017 at 3:00 p.m. ET. In addition, ... day. A live audio webcast will be ...
(Date:3/22/2017)... JACKSONVILLE, Fla. , March 22, 2017 /PRNewswire/ ... clinical-stage immuno-oncology company specializing in the development of ... of cancer and metastatic disease, today announced that ... Industry conferences. Dr. Glynn Wilson ... an overview of the company,s business, clinical pipeline ...
(Date:3/22/2017)... 22, 2017 Hologic, Inc. (Nasdaq: ... acquisition of Cynosure, Inc., a leader in medical aesthetics ... "We are pleased to complete our acquisition ... Michael Davin and the entire Cynosure team to ... medical aesthetics market," said Steve MacMillan , Hologic,s ...
Breaking Medicine Technology: